Screening for inhibitors of allergen-associated airway smooth muscle contraction
筛选过敏原相关气道平滑肌收缩抑制剂
基本信息
- 批准号:10176398
- 负责人:
- 金额:$ 21.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAffinityAlamarBlueAllergensAllergic inflammationAnimalsAntifungal AgentsAspergillus fumigatusAsthmaBiological AssayBiological SciencesBronchoconstrictionBronchodilator AgentsCell SurvivalCytoskeletonDataDinoprostoneDiseaseDoseEvaluationExtracellular MatrixFocal AdhesionsGene ExpressionGenerationsHumanHypersensitivityIgEInflammatoryInhalationLeadLifeLungMeasurementMediatingMediator of activation proteinMoldsMucous MembraneMusMuscle ContractionMycosesN-CadherinPatientsPeptide HydrolasesProductionSafetySchemeSerine ProteaseSerine Proteinase InhibitorsSignal PathwaySliceSmooth Muscle MyocytesStress FibersSubmucosaSymptomsTestingTherapeuticToxic effectValidationaggressive therapyairway hyperresponsivenessalkalinityanti-IgEasthmaticasthmatic airway smooth muscleasthmatic patientattenuationbasecomparativeconstrictioncytokinecytotoxicitydesigndrug candidatedruggable targetexperiencefollow-upfungushigh throughput screeningin vivoinhibitor/antagonistinsightnovelomalizumabprecision medicineprotein expressionpublic health relevancerespiratory smooth musclescreeningsmall molecular inhibitorsmall molecule inhibitortherapeutic target
项目摘要
PROJECT SUMMARY
Despite aggressive treatment with high-dose inhaled corticosteroids plus bronchodilators, approximately 5-10%
of people with asthma (15-30 million) experience severe and life-threatening symptoms of bronchoconstriction.
Nearly one-half of these severe asthma patients are also “sensitized” (i.e. have IgE mediated allergy) to common
molds such as Aspergillus fumigatus (Af). This condition has now been recognized as a distinct entity and
designated fungal asthma (FA). Unfortunately, current therapies for FA—antifungals and/or omalizumab (anti-
IgE)—have not proven to be efficacious in the long-term.
By studying Af-induced bronchoconstriction in mice and people with asthma, our team has discovered a novel,
direct, and druggable target in FA—the Af allergen-derived serine protease, alkaline protease 1 (Alp1). Alp1
promotes the defining symptom of FA—bronchoconstriction—by inducing airway smooth muscle (ASM)
contraction, through mechanisms that appear to be independent of allergic inflammation. In this application, we
will pursue the hypothesis that inhibitors of Alp1-induced human ASM contraction can be discovered by high
throughput screening (HTS). In aim 1, we will use HTS to identify small molecular inhibitors of Alp1 protease. In
aim 2, we will examine the effects of FA pathobiology on the efficacy of Alp1-inhibitor therapy. In aim 3, we will
determine mechanism and examine significance for Alp1-inhibitor therapy. We expect our approach to identify
novel anti-FA drug candidates, and in doing so, offer substantial insight into both ASM-intrinsic and allergen
protease dependent mechanisms of bronchoconstriction.
项目摘要
尽管用高剂量遗传性皮质类固醇加上支气管扩张剂进行了积极的治疗,但约为5-10%
哮喘(15-30亿)患者经历了严重的危害生命的支气管收缩症状。
这些严重的哮喘患者中有将近一半也“敏感”(即对IgE介导的过敏)对常见
烟曲霉(AF)等霉菌。现在,这种情况已被认为是一个独特的实体,
指定的真菌哮喘(FA)。不幸的是,FA的当前疗法 - 抗直导和/或Omalizumab(抗
IGE) - 从长远来看,未被证明是有效的。
通过研究小鼠和患有哮喘患者的AF诱导的支气管收缩,我们的团队发现了一部小说,
FA中的直接且可吸毒的靶标 - AF过敏原衍生的丝氨酸蛋白酶,酒精蛋白酶1(ALP1)。
通过诱导的气道平滑肌(ASM)来促进FA的定义症状(支核收缩)
收缩,通过似乎独立于过敏注射的机制。在此应用程序中,我们
将提出以下假设:ALP1诱导的人ASM收缩的抑制剂可以通过高
吞吐量筛选(HTS)。在AIM 1中,我们将使用HTS鉴定ALP1蛋白酶的小分子抑制剂。在
AIM 2,我们将研究FA病理生物学对ALP1抑制剂疗法有效性的影响。在AIM 3中,我们将
确定ALP1抑制剂疗法的机制和检查显着性。我们希望我们的方法可以识别
新颖的抗FA候选药物,并在此过程中对ASM Intrinsic和过敏原提供了实质性的见解
支气管收缩的蛋白酶依赖性机制。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Multiscale stiffness of human emphysematous precision cut lung slices.
- DOI:10.1126/sciadv.adf2535
- 发表时间:2023-05-19
- 期刊:
- 影响因子:13.6
- 作者:Kim, Jae Hun;Schaible, Niccole;Hall, Joseph K.;Bartolak-Suki, Erzsebet;Deng, Yuqing;Herrmann, Jacob;Sonnenberg, Adam;Behrsing, Holger P.;Lutchen, Kenneth R.;Krishnan, Ramaswamy;Suki, Bela
- 通讯作者:Suki, Bela
CD38 plays an age-related role in cholinergic deregulation of airway smooth muscle contractility.
- DOI:10.1016/j.jaci.2021.10.033
- 发表时间:2022-05
- 期刊:
- 影响因子:14.2
- 作者:Bai, Yan;Guedes, Alonso G. P.;Krishnan, Ramaswamy;Ai, Xingbin
- 通讯作者:Ai, Xingbin
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RAMASWAMY KRISHNAN其他文献
RAMASWAMY KRISHNAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RAMASWAMY KRISHNAN', 18)}}的其他基金
Screening for inhibitors of allergen-associated airway smooth muscle contraction
筛选过敏原相关气道平滑肌收缩抑制剂
- 批准号:
10057021 - 财政年份:2020
- 资助金额:
$ 21.88万 - 项目类别:
Cooperative targeting of pharmacomechanical coupling and the actin cytoskeleton to regulate ASM contraction
药物机械耦合和肌动蛋白细胞骨架的协同靶向调节 ASM 收缩
- 批准号:
9983151 - 财政年份:2019
- 资助金额:
$ 21.88万 - 项目类别:
Cooperative targeting of pharmacomechanical coupling and the actin cytoskeleton to regulate ASM contraction
药物机械耦合和肌动蛋白细胞骨架的协同靶向调节 ASM 收缩
- 批准号:
10188621 - 财政年份:2019
- 资助金额:
$ 21.88万 - 项目类别:
Cooperative targeting of pharmacomechanical coupling and the actin cytoskeleton to regulate ASM contraction
药物机械耦合和肌动蛋白细胞骨架的协同靶向调节 ASM 收缩
- 批准号:
10434061 - 财政年份:2019
- 资助金额:
$ 21.88万 - 项目类别:
Monitoring contractile forces during airway constriction
监测气道收缩期间的收缩力
- 批准号:
9318550 - 财政年份:2016
- 资助金额:
$ 21.88万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:
10752555 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Strategies for next-generation flavivirus vaccine development
下一代黄病毒疫苗开发策略
- 批准号:
10751480 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Regulation of coronavirus cross-reactivity and immune durability for pan-coronavirus vaccine development
泛冠状病毒疫苗开发中冠状病毒交叉反应性和免疫耐久性的调节
- 批准号:
478959 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Operating Grants
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Grant-in-Aid for JSPS Fellows